AAAAAA
Results: 1-25/128
Authors:
VANHEMS P
LAMBERT J
COOPER DA
PERRIN L
CARR A
HIRSCHEL B
VIZZARD J
KINLOCHDELOES SK
ALLARD R
Citation: P. Vanhems et al., SEVERITY AND PROGNOSIS OF ACUTE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ILLNESS - A DOSE-RESPONSE RELATIONSHIP, Clinical infectious diseases, 26(2), 1998, pp. 323-329
Authors:
ASHTON LJ
CARR A
CUNNINGHAM PH
ROGGENSACK M
MCLEAN K
LAW M
ROBERTSON M
COOPER DA
KALDOR JM
Citation: Lj. Ashton et al., PREDICTORS OF PROGRESSION IN LONG-TERM NONPROGRESSORS, AIDS research and human retroviruses, 14(2), 1998, pp. 117-121
Authors:
CARR A
SAMARAS K
BURTON S
LAW M
FREUND J
CHISHOLM DJ
COOPER DA
Citation: A. Carr et al., A SYNDROME OF PERIPHERAL LIPODYSTROPHY, HYPERLIPIDEMIA AND INSULIN-RESISTANCE IN PATIENTS RECEIVING HIV PROTEASE INHIBITORS, AIDS, 12(7), 1998, pp. 51-58
Authors:
KELLEHER AD
ROGGENSACK M
JARAMILLO AB
SMITH DE
WALKER A
GOW I
MCMURCHIE M
HARRIS J
PATOU G
COOPER DA
Citation: Ad. Kelleher et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE THERAPEUTIC VACCINE, P24 VIRUS-LIKE PARTICLE, COMBINED WITH ZIDOVUDINE, IN ASYMPTOMATIC SUBJECTS, AIDS, 12(2), 1998, pp. 175-182
Authors:
KAUFMANN GR
DUNCOMBE C
CUNNINGHAM P
BEVERIDGE A
CARR A
SAYER D
FRENCH M
COOPER DA
Citation: Gr. Kaufmann et al., TREATMENT RESPONSE AND DURABILITY OF A DOUBLE PROTEASE INHIBITOR THERAPY WITH SAQUINAVIR AND RITONAVIR IN AN OBSERVATIONAL COHORT OF HIV-1-INFECTED INDIVIDUALS, AIDS, 12(13), 1998, pp. 1625-1630
Authors:
ABOULKER JP
BABIKER AG
CLUMECK N
COOPER DA
DARBYSHIRE JH
DORMONT J
GATELL J
GOEBEL F
LAURIAN Y
MANNUCCI P
MATHIESEN L
PETO TEA
REISS P
SANDSTROM E
SAVIDGE G
SELIGMANN M
SMITH D
STINGL G
VEENSTRA J
WELLER IVD
YEO J
LAFON E
MCCORMACK S
SWART AM
WITHNALL R
Citation: Jp. Aboulker et al., LONG-TERM FOLLOW-UP OF RANDOMIZED TRIALS OF IMMEDIATE VERSUS DEFERREDZIDOVUDINE IN SYMPTOM-FREE HIV-INFECTION, AIDS, 12(11), 1998, pp. 1259-1265
Authors:
CARR A
SAMARAS K
CHISHOLM DJ
COOPER DA
Citation: A. Carr et al., PATHOGENESIS OF HIV-1-PROTEASE INHIBITOR-ASSOCIATED PERIPHERAL LIPODYSTROPHY, HYPERLIPIDEMIA, AND INSULIN-RESISTANCE, Lancet, 351(9119), 1998, pp. 1881-1883
Authors:
CARR A
SAMARAS K
CHISHOLM DJ
COOPER DA
Citation: A. Carr et al., ABNORMAL FAT DISTRIBUTION AND USE OF PROTEASE INHIBITORS, Lancet, 351(9117), 1998, pp. 1736-1736
Authors:
CARR A
MARRIOTT D
FIELD A
VASAK E
COOPER DA
Citation: A. Carr et al., TREATMENT OF HIV-1-ASSOCIATED MICROSPORIDIOSIS AND CRYPTOSPORIDIOSIS WITH COMBINATION ANTIRETROVIRAL THERAPY, Lancet, 351(9098), 1998, pp. 256-261
Authors:
WONG KH
COOPER DA
PIGOTT P
MARRIOTT DJ
Citation: Kh. Wong et al., CHRONIC COUGH IN PATIENTS WITH HIV-INFECTION, Scandinavian journal of infectious diseases, 30(3), 1998, pp. 227-229
Authors:
CARR A
COOPER DA
Citation: A. Carr et Da. Cooper, LIPODYSTROPHY ASSOCIATED WITH AN HIV-PROTEASE INHIBITOR, The New England journal of medicine, 339(18), 1998, pp. 1296-1296
Authors:
COOPER DA
EMERY S
Citation: Da. Cooper et S. Emery, THERAPEUTIC STRATEGIES FOR HIV-INFECTION - TIME TO THINK HARD, The New England journal of medicine, 339(18), 1998, pp. 1319-1321
Authors:
CARR A
EMERY S
LLOYD A
HOY J
GARSIA R
FRENCH M
STEWART G
FYFE G
COOPER DA
Citation: A. Carr et al., OUTPATIENT CONTINUOUS INTRAVENOUS INTERLEUKIN-2 OR SUBCUTANEOUS, POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS - A RANDOMIZED, CONTROLLED, MULTICENTER STUDY, The Journal of infectious diseases, 178(4), 1998, pp. 992-999
Authors:
GOLDSTEIN D
HERTZOG P
TOMKINSON E
COULDWELL D
MCCARVILLE S
PARRISH S
CUNNINGHAM P
NEWELL M
OWENS M
COOPER DA
Citation: D. Goldstein et al., ADMINISTRATION OF IMIQUIMOD, AN INTERFERON INDUCER, IN ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS TO DETERMINE SAFETY AND BIOLOGIC RESPONSE MODIFICATION, The Journal of infectious diseases, 178(3), 1998, pp. 858-861
Authors:
IOANNIDIS JPA
COLLIER AC
COOPER DA
COREY L
FIDDIAN AP
GAZZARD BG
GRIFFITHS PD
CONTOPOULOSIOANNIDIS DG
LAU J
PAVIA AT
SAAG MS
SPRUANCE SL
YOULE MS
Citation: Jpa. Ioannidis et al., CLINICAL EFFICACY OF HIGH-DOSE ACYCLOVIR IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A METAANALYSIS OF RANDOMIZED INDIVIDUAL PATIENT DATA, The Journal of infectious diseases, 178(2), 1998, pp. 349-359
Authors:
MOYLE GJ
GAZZARD BG
COOPER DA
GATELL J
Citation: Gj. Moyle et al., ANTIRETROVIRAL THERAPY FOR HIV-INFECTION - A KNOWLEDGE-BASED APPROACHTO DRUG SELECTION AND USE, Drugs, 55(3), 1998, pp. 383-404
Authors:
KELLEHER AD
ROGGENSACK M
EMERY S
CARR A
FRENCH MA
COOPER DA
Citation: Ad. Kelleher et al., EFFECTS OF IL-2 THERAPY IN ASYMPTOMATIC HIV-INFECTED INDIVIDUALS ON PROLIFERATIVE RESPONSES TO MITOGENS, RECALL ANTIGENS AND HIV-RELATED ANTIGENS, Clinical and experimental immunology, 113(1), 1998, pp. 85-91
Authors:
MCNULTY A
LAW MG
BODSWORTH NJ
COOPER DA
KALDOR JM
Citation: A. Mcnulty et al., INCIDENCE OF HIV-INFECTION IN A COHORT OF HOMOSEXUALLY ACTIVE MEN, Australian and New Zealand journal of public health, 21(6), 1997, pp. 587-589
Authors:
DORE GJ
HOY JF
MALLAL SA
LI YM
MIJCH AM
FRENCH MA
COOPER DA
KALDOR JM
Citation: Gj. Dore et al., TRENDS IN INCIDENCE OF AIDS ILLNESSES IN AUSTRALIA FROM 1983 TO 1994 - THE AUSTRALIAN AIDS COHORT, Journal of acquired immune deficiency syndromes and human retrovirology, 16(1), 1997, pp. 39-43
Authors:
CARR A
COOPER DA
Citation: A. Carr et Da. Cooper, CD8 T-CELL RESPONSE TO ANTIRETROVIRAL THERAPY - REPLY, Journal of acquired immune deficiency syndromes and human retrovirology, 15(2), 1997, pp. 176-177
Authors:
NEWELL M
MILLIKEN S
CHIPMAN M
CEBON J
LEWIS C
GOLDSTEIN D
COOPER DA
Citation: M. Newell et al., DOX-SL (STEALTH LIPOSOMAL DOXORUBICIN HCL) MAINTENANCE THERAPY AFTER RESPONSE IN AIDS-RELATED KAPOSIS-SARCOMA, Journal of acquired immune deficiency syndromes and human retrovirology, 14(4), 1997, pp. 15-15
Authors:
VANHEMS P
ALLARD R
COOPER DA
PERRIN L
VIZZARD J
HIRSCHEL B
KINLOCHDELOES S
CARR A
LAMBERT J
Citation: P. Vanhems et al., ACUTE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DISEASE AS A MONONUCLEOSIS-LIKE ILLNESS - IS THE DIAGNOSIS TOO RESTRICTIVE, Clinical infectious diseases, 24(5), 1997, pp. 965-970
Authors:
EMERY S
COOPER DA
Citation: S. Emery et Da. Cooper, DRUG COMPANIES HAVE A DUTY TO CONTINUE TREATMENT, BMJ. British medical journal, 314(7084), 1997, pp. 889-889
Authors:
KELLEHER AD
EMERY S
CUNNINGHAM P
DUNCOMBE C
CARR A
GOLDING H
FORDE S
HUDSON J
ROGGENSACK M
FORREST BD
COOPER DA
Citation: Ad. Kelleher et al., SAFETY AND IMMUNOGENICITY OF UBI HIV-1(MN) OCTAMERIC V3 PEPTIDE VACCINE ADMINISTERED BY SUBCUTANEOUS INJECTION, AIDS research and human retroviruses, 13(1), 1997, pp. 29-32
Authors:
MILDVAN D
COOPER DA
Citation: D. Mildvan et Da. Cooper, CLINICAL TREATMENT, AIDS, 11, 1997, pp. 139-139